June 5, 2019Journal of Thrombosis and ThrombolysisOpen Access

What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial

View Full Paper

Ask AI

Bookmark

Why the study?

Studies using DOACs in cancer patients include few with myeloma, leaving safety concerns and the feasibility of a multicentre trial uncertain.

Is apixaban safe and feasible compared to standard thromboprophylaxis in newly diagnosed multiple myeloma patients?

Comparison

Standard thromboprophylaxis vs apixaban 2.5 mg BD

Design

Randomised feasibility clinical trial

Follow-up

Throughout chemotherapy

Authors

ZSZara SayarWhittington Hospital JCJulia CzuprynskaKing's College Hospital NHS Foundation Trust JPJignesh P. PatelGandhi Medical College & Hospital

Discussion

Member takes

Implication

Apixaban TP appears feasible in NDMM; leaves open safety and efficacy confirmation in larger randomized trials.

Structured PICO

Is apixaban safe and feasible compared to standard thromboprophylaxis in newly diagnosed multiple myeloma patients?

Population

10 newly diagnosed multiple myeloma (NDMM) patients undergoing chemotherapy (2 high VTE risk, 8 standard risk)

Intervention

Apixaban 2.5 mg twice daily (BD)

Comparator

Standard thromboprophylaxis (aspirin for standard risk patients or low molecular weight heparin for high risk patients)

Outcome

Feasibility of creating a multicentre trial and safety concerns (major bleeding or VTE events)safety

A feasibility trial of apixaban versus standard thromboprophylaxis in newly diagnosed multiple myeloma showed no major bleeding or VTE events, highlighting the potential for larger co-recruitment trials.

Limitations

Small sample size (n=10)

Cite This Study

Sayar et al. (2019) studied this question.

synapsesocial.com/papers/6a8bafdf0ca85c7e33df015f https://doi.org/10.1007/s11239-019-01891-0

View Full Paper

Ask AI

Bookmark

What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider